Clinical Trials Logo

Parkinson's Disease clinical trials

View clinical trials related to Parkinson's Disease.

Filter by:
  • Enrolling by invitation  
  • Page 1 ·  Next »

NCT ID: NCT06164756 Enrolling by invitation - Depression Clinical Trials

Long Term Follow Up KET-PD

Start date: October 18, 2023
Phase:
Study type: Observational

The purpose of this study is to examine a) the longer-term effects of ketamine for treating depression in Parkinson's disease (PD) and b) the effects of CBT on maintaining the effects of ketamine.

NCT ID: NCT06099886 Enrolling by invitation - Parkinson's Disease Clinical Trials

Repurposing Lithium for Parkinson's Disease

Start date: October 12, 2023
Phase: Phase 1
Study type: Interventional

This study will examine the effects of lithium aspartate 30-45mg/day on MRI biomarkers and blood-based therapeutic targets among 15 early-stage Parkinson's disease patients.

NCT ID: NCT05543252 Enrolling by invitation - Parkinson's Disease Clinical Trials

An Extension Study to Evaluate the Long-Term Efficacy, Safety and Tolerability of Minzasolmin (UCB0599) in Study Participants With Parkinson's Disease

Start date: August 29, 2022
Phase: Phase 2
Study type: Interventional

The purpose of the study is to estimate the pharmacodynamic effects of minzasolmin (UCB0599) on brain pathophysiology in Early-start versus Delayed-start participants originally diagnosed with new onset Parkinson's disease.

NCT ID: NCT05173701 Enrolling by invitation - Parkinson's Disease Clinical Trials

Effects of Probiotics on Peripheral Immunity in Parkinson's Disease

Start date: November 22, 2021
Phase: N/A
Study type: Interventional

Parkinson's Disease (PD) is a common neurodegenerative disease, with no disease-modifying treatment available, therapy is therefore only symptomatic. The pathophysiology of the disease is still unclear, but inflammatory mechanisms are reported to play a prominent role. An involvement of peripheral adaptive immunity, with an imbalance in T cell subpopulations and in the expression of transcriptional factors (TF) in Cluster of Differentiation (CD) 4 positive T cells has been reported. An initial aggregation of α-synuclein (α-syn) in the gut with subsequent propagation along the vagus nerve to the brain has also been hypothesised. Interestingly, in an α-syn overexpressing murine model, the absence of gut microbiota prevented both microglia activation and motor impairment, pointing to a fundamental role of the microbiota in the development of PD. It has been shown that in Peripheral Blood Mononuclear Cells (PBMC) of PD patients, probiotics modulate the in vitro production of cytokines toward an anti-inflammatory profile. The investigators developed a clinical trial protocol for the evaluation of probiotics' effects on the peripheral immune system profile in Parkinson's Disease patients. ROS, Lymphocyte subpopulations, TF levels in PBMC will be assessed at baseline and after treatment with a mixture of probiotics in PD patients to assess immunomodulatory effects of said treatment. Motor and non-motor symptoms of PD will also be monitored through the trial period.

NCT ID: NCT04651140 Enrolling by invitation - Parkinson's Disease Clinical Trials

Research on the Effect and Mechanism of Aerobic Exercise on PD

Start date: October 13, 2020
Phase: N/A
Study type: Interventional

This trial is expected to recruit patients with primary Parkinson's disease and give them four consecutive weeks of aerobic exercise to observe its effect on Parkinson's disease and explore its mechanism

NCT ID: NCT04593511 Enrolling by invitation - Parkinson's Disease Clinical Trials

to Evaluate the Safety, Tolerability and Pharmacokinetics of Four Formulations of LY03009 in Healthy Volunteers

Start date: February 2, 2021
Phase: Phase 1
Study type: Interventional

The purpose of this study is to Evaluate the Safety, Tolerability and Pharmacokinetics of Four Formulations of LY03009 in Healthy Volunteers.

NCT ID: NCT03837314 Enrolling by invitation - Parkinson's Disease Clinical Trials

Simpler and Safer Deep Brain Stimulation for Parkinson's Disease

SPARKS
Start date: October 28, 2020
Phase: N/A
Study type: Interventional

The aim is to improve availability and acceptability of deep brain stimulation (DBS) for the treatment of Parkinson by shortening and simplifying the implantation procedure, thereby reducing time in surgery, complexity, post-surgery complications and cost, and increasing patient satisfaction. To facilitate the shortening and simplifying of the implantation procedure, a miniaturised skull-mounted DBS device (Picostim) has been developed which is optimised to generate waveforms needed for stimulation of the subthalamic nucleus (STN) and STN region, employing a unique method of controlling stimulation current. The planned study is a single centre, open label, non-randomised design with the primary objective of showing similarity in control of motor symptoms for the Picostim device compared with previously published data for existing DBS devices.

NCT ID: NCT03550183 Enrolling by invitation - Parkinson's Disease Clinical Trials

Umbilical Cord Derived Mesenchymal Stem Cells Therapy in Parkinson's Disease

Start date: January 10, 2018
Phase: Phase 1
Study type: Interventional

This study is to evaluate the safety and efficacy of Umbilical Cord Derived Mesenchymal Stem Cells transplantation in Parkinson's disease.

NCT ID: NCT03258294 Enrolling by invitation - Parkinson's Disease Clinical Trials

Effect of Melatonin on Sleep Disturbances in Patients With Parkinson's Disease

Start date: January 13, 2016
Phase: Phase 4
Study type: Interventional

This clinical study is a double-blind, randomized, placebo-controlled trial to investigate the effects of melatonin on the sleep disturbance symptoms of Parkinson's disease patients, symptoms which have a significant impact on the quality of life of these patients.

NCT ID: NCT02768077 Enrolling by invitation - Parkinson's Disease Clinical Trials

Effect of Melatonin on Sleep Disturbances in Patients With Parkinson's Disease

Start date: January 2016
Phase: Phase 4
Study type: Interventional

This clinical study is a double-blind, randomized, placebo-controlled trial to investigate the effects of melatonin on the sleep disturbance symptoms of Parkinson's disease patients, symptoms which have a significant impact on the quality of life of these patients.